Blog
-
-
International Women’s Day 2021
-
Rare Disease Healthcare Spending Tops Costly Chronic Diseases
-
Merck follows Bristol’s suit, pulling Keytruda’s SCLC nod. Is the FDA’s accelerated approval reckoning finally here?
-
After Imfinzi’s double flop, AstraZeneca walks away from FDA bladder cancer nod
-
Bluebird suspends studies of sickle cell gene therapy following cancer diagnoses in two more treated patients
-
A gene therapy pipeline takes shape for a cluster of rare diseases
-
ASCO GU: Bristol Myers touts first-in-class Opdivo win in muscle-invasive bladder cancer
-
FDA weighs tighter restrictions for Pfizer’s Xeljanz on the heels of safety red flags
-
Gene therapy for hemophilia: So close, yet so far away